New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
04:55 EDTBLUE, BLUE, BLUE, BLUE, ACE, ACE, ACE, ACE, XLRN, XLRN, XLRN, XLRN, TGTX, TGTX, TGTX, TGTX, NVS, NVS, NVS, NVS, AGIO, AGIO, AGIO, AGIO, AG, AG, AG, AGEuropean Hematology Association to hold a conference
19th Congress of the European Hematology Association will be held in Milan, Italy on June 12-15.
News For BLUE;ACE;XLRN;TGTX;NVS;AGIO;AG From The Last 14 Days
Check below for free stories on BLUE;ACE;XLRN;TGTX;NVS;AGIO;AG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 21, 2014
18:13 EDTTGTXTG Therapeutics to host conference call
Subscribe for More Information
16:30 EDTTGTXTG Therapeutics up 4.3% after reporting Q2 results, preclinical study results
16:15 EDTTGTXTG Therapeutics reports preliminary clinical results from TG-1101 Phase I study
TG Therapeutics announced preliminary clinical results from its ongoing Phase I study of TG-1101, the company's novel glycoengineered anti-CD20 monoclonal antibody in combination with TGR-1202, the company's novel, once-daily PI3K delta inhibitor in patients with advanced CLL and non-Hodgkin's lymphoma. 100% of CLL/SLL patients had significant nodal reduction with either a normalization of or greater than or equal to 80% reduction in Blood Lymphocyte Count. 4 of 5 CLL/SLL patients achieved a partial response at first assessment, including a patient relapsed from a prior BTK-inhibitor, and the 5th patient with stable disease achieved a 44% nodal reduction pending next assessment. 2 of 5 heavily pretreated DLBCL patients achieved a PR, including one patient with GCB subtype refractory to prior therapy. Combination appears well tolerated with no dose-related increases in toxicity observed among patients treated to date
16:13 EDTTGTXTG Therapeutics reports Q2 EPS (36c), consensus (24c)
Subscribe for More Information
07:38 EDTNVSNovartis management to meet with JPMorgan
Meetings to be held in Los Angeles/Pasadena on July 24 and in San Francisco on July 25 hosted by JPMorgan.
07:13 EDTTGTXUniversity of Nebraska Medical Center to hold a conference
2014 Pan Pacific Lymphoma Conference to be held in Kohala Coast, Hawaii on July 21-25.
07:11 EDTNVSInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
07:03 EDTNVSAnacor, Sandoz enter into agreement for commercialization of Kerydin in the U.S.
Anacor Pharmaceuticals (ANAC) announced that it has entered into an exclusive agreement with Sandoz, a Novartis (NVS) company, pursuant to which Sandoz will distribute and commercialize Anacorís drug KERYDIN topical solution, 5% in the United States. PharmaDerm, the branded dermatology business of Sandoz, will be responsible for the sales and marketing of KERYDIN. On July 8, Anacor announced that the U.S. FDA approved the New Drug Application for KERYDIN, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today. The agreement with Sandoz entitles Anacor to upfront payments totaling $40M and an additional milestone payment of $25M expected to be paid in January 2015. Under the agreement, Sandoz and Anacor will share equally, under a long-term profit-sharing arrangement, the gross profits accrued by Sandoz on sales of KERYDIN, except that in 2015 Anacor will start receiving profit-sharing payments after the first $50M of gross profits have been accrued by Sandoz. The long-term profit-sharing arrangement includes cumulative minimum profit-sharing payments to Anacor in 2016 totaling $45M. Anacor will also have the option to repurchase all rights in KERYDIN from Sandoz on the later of three years from launch or December 31, 2017, at a price to be determined pursuant to the agreement. Under the terms of the agreement, Anacor will supply product to Sandoz at cost through Anacorís contract manufacturers, and Sandoz will be responsible for all of its selling, marketing, distribution, general and administrative costs related to the commercialization of KERYDIN. Anacor will hold the NDA and will be responsible for any further development of KERYDIN.
July 17, 2014
11:56 EDTBLUEbluebird bio mentioned positively by The Street's Dan Rosenblum
Subscribe for More Information
08:34 EDTNVSVanda requests award of $539M in proceedings with Novartis
Subscribe for More Information
05:32 EDTNVSNovartis reconfirms FY14 revenue guidance up at low to mid single digit rate
The company stated, "We are reconfirming our outlook for FY14. Group net sales in 2014 are expected to grow at a low to mid-single digit rate. Group core operating income is expected to grow ahead of sales in 2014, and now refined to mid to high-single digit. This outlook recognizes the entry of generic competition for Diovan monotherapy in the U.S. on July 7, including an authorized generic from Sandoz on the same date. If June average exchange rates prevail for the remainder of the year, the currency impact for the year would be -1% on sales and -3% to -4% on core operating income."
05:29 EDTNVSNovartis reports Q2 Core EPS $1.34, consensus $1.42
Reports Q2 revenue $14.6B, consensus $14.81B. Reports continued pipeline progress with positive regulatory decisions and significant clinical trial data released in Q2.
July 15, 2014
05:44 EDTNVSNovartis to license Google 'smart lens' technology
Novartis (NVS) announced that its eye care division Alcon has entered into an agreement with a division of Google (GOOG) to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to transform eye care and further enhance Alcon's pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals. The agreement between Google and Alcon represents an important step for Novartis, across all of its divisions, to leverage technology to manage human diseases and conditions. Google's key advances in the miniaturization of electronics complement Novartis's deep pharmaceuticals and medical device expertise. Novartis aims to enhance the ways in which diseases are mapped within the body and ultimately prevented.
05:35 EDTNVSNovartis collaborates with Banner Alzheimer's Institute on study
Novartis announced a collaboration with Banner Alzheimer's Institute, or BAI, on a pioneering clinical study in Alzheimer's disease, or AD, prevention. The study will determine whether two Novartis investigational anti-amyloid treatments can prevent or delay the emergence of symptoms of AD in people identified as being at genetic risk for developing the late-onset form of the disease. Using an innovative trial design, the two treatments will be given in cognitively healthy people at genetic risk of developing the build-up of amyloid protein in the brain that may eventually lead to AD. One treatment is an active immunotherapy, a treatment that stimulates an immune response, and triggers the production of natural antibodies against amyloid. This investigational treatment, given via an injection, is in phase II clinical development. The second treatment, a BACE inhibitor, is an oral medication about to enter phase I trials and is designed to prevent the production of different forms of amyloid.
July 14, 2014
07:23 EDTNVSAlzheimer's Association to hold a conference
Subscribe for More Information
07:04 EDTAGFirst Majestic announces spin-out of non-core exploration properties
Subscribe for More Information
07:02 EDTAGFirst Majestic announces 3.86M silver eqv. ounces produced in Q2
First Majestic announced that total production at its five operating silver mines in Mexico for the second quarter reached a new quarterly record of 3,855,224 equivalent ounces of silver, representing an 18% increase compared to the same quarter in 2013. Total silver production for the quarter consisted of 3,098,218 ounces of silver, representing an increase of 12% compared to the same quarter in 2013. In addition, 9,131,149 pounds of lead and 2,637,967 pounds of zinc were produced, representing an increase of 54% and a decrease of 9%, respectively, compared to the same quarter of the previous year. Also produced were 2,801 ounces of gold, representing an increase of 40% compared to the second quarter of 2013. The total ore processed during the quarter at the Company's five operating silver mines: La Encantada, La Parrilla, Del Toro, San Martin and La Guitarra, amounted to 671,024 tonnes, reflecting no significant variation year-over-year and represents a 5% increase over the previous quarter.
July 10, 2014
15:43 EDTNVSNovartis siponimod designated as orphan treatment of dermatomyositis
Subscribe for More Information
14:28 EDTXLRNT. Rowe Price reports 10.4% passive stake in Acceleron
Subscribe for More Information
11:00 EDTAGHigh option volume stocks
High option volume stocks: CBS MEMP EWT CBSO DRWI TRW TTS EXK MEOH AG
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use